Is Kratom Safe?

Nobody can honestly tell you kratom is safe. We can’t, and neither can anyone else selling it to you.

Think of a knife on a kitchen counter. On its own, it isn’t safe and it isn’t dangerous. It becomes one or the other depending on who picks it up and whether they’re paying attention. Kratom works the same way. The honest answer is that it depends on you, and this level is about the choices that answer rests on.

Natural Does Not Mean Harmless

Poison ivy is natural. So is the poppy. Nature doesn’t sort plants into safe and unsafe for our convenience. What a compound does depends on the amount and the person, and on what else is in that person at the time.

The leaf holds dozens of alkaloids, and as you saw in the last level, how much of each it carries moves from tree to tree and batch to batch. So two packages of kratom aren’t necessarily the same thing. That is true across brands and product types, and to some degree across batches from the same field¹. It is why we test. It’s also why nobody, us included, can tell you what a given amount will do inside you.

What the Clinical Trials Found

In 2026, FDA scientists published a pilot study of botanical kratom. Forty people took part, in five groups of eight. In each group, six received kratom and two received a placebo. The amount given rose in five steps, and each step went ahead only after a safety review cleared the one before it. The material was leaf, with alkaloid levels that matched botanical kratom products already described in the literature.

There were no deaths and no serious adverse events. The most common adverse effects were sleepiness, vomiting and nausea. Pupillary constriction, an opioid-type effect, showed up at all but the lowest amount. At the largest amount, participants reported more of the subjective effects that mark substances people come back to.

A larger trial, published in January 2026, tested characterized dried leaf powder against a placebo in 116 healthy volunteers. They took it once, then daily for fifteen days. It reported no serious adverse events and no deaths, and its authors concluded the powder was well tolerated at the amounts tested.

Who Was Actually in the Room

Here is the part that’s easy to skip. The FDA pilot recruited people who take drugs recreationally and had prior opioid experience, all screened to be otherwise healthy. The larger trial recruited healthy nonsmokers aged 18 to 55, inside a set weight range, who had either never taken kratom or hadn’t touched it in a year or more. Both groups took one well-characterized product under monitoring.

Almost nobody buying kratom is in that room. Real customers take other medications. They drink. They have liver and kidney histories. They buy products of varying and undisclosed alkaloid content, and many take them daily over long stretches. The pilot’s own authors say their results may not represent other kratom-containing products.

The Other Half of the Record

In March 2026, the CDC reported its analysis of poison center data². Poison centers logged 14,449 kratom exposure reports between 2015 and 2025. Reports held roughly level from 2020 to 2024, then jumped in 2025 to a record 3,434. The CDC connected that jump to the arrival of synthetic products sold under the name 7-OH. Those aren’t leaf, and they aren’t what we sell. The CDC also says its data can’t be separated by product type, so nothing in that record clears leaf either.

Across those eleven years, poison centers recorded 233 kratom-associated deaths. Of those, 184, or 79 percent, involved more than one substance. Opioids appeared in 62 percent, and benzodiazepines, stimulants and alcohol in roughly 20 percent each. Where several substances were reported, the authors couldn’t determine which one drove the outcome. Kratom-associated isn’t the same as kratom-caused. It also isn’t nothing.

Why the Case Reports Are Weaker Than Either Side Admits

Most of what gets quoted about kratom harm comes from case reports³, which means one clinician writing up one patient. A 2025 review went through 59 of those papers, covering 95 patients. Toxicology confirmed mitragynine in 55 of them. For the other 40, there was no confirmation that kratom was present at all, and some of those write-ups blamed kratom anyway.

Among the 55 confirmed cases, other substances turned up in 32 of the 35 who died, and in 7 of the 20 who lived. Blood concentrations didn’t separate the two groups. In fact, the lowest level measured among those who died was below the lowest measured among those who lived. That is exactly why we won’t print a number here.

We owe you one more detail, because that review helps us. Its authors work for a consulting firm engaged by kratom processors in litigation, and they disclose it in the paper. We’d flag that without a second thought if the finding had gone the other way, so we are flagging it now.

So the Answer Is Yours

Picture somebody who takes an unknown product every day for several years. The trials tell you almost nothing about that person, because that person hasn’t been studied.

Risk isn’t a fixed property of the plant. It lives in the amount, the frequency, the product, and above all in what else you are taking. Those are your decisions, not the plant’s, and the rest of this level is about making them on purpose. If you’d rather read on paper, the Responsible Use Guide, Print Edition⁴ summarizes the whole section this level draws on. It is one free file you can print.

Key Takeaways

• There’s no yes or no answer, and anyone who gives you one is selling something. Kratom is a tool, and the risk sits in how it is handled. That’s what responsible use means.
• Combination is the most consistent finding in the whole safety record. Of 233 kratom-associated deaths poison centers recorded over eleven years, 79 percent involved more than one substance.
• No safe amount and no safe frequency have been established, so no number can be your guardrail. What you control is what else you take, how often, and how well you know your product.
• Two kratom products aren’t the same thing. Alkaloid content varies from tree to tree and batch to batch.
• The trials studied screened people taking one known product for a short time. Nobody has studied the person who buys retail and takes it daily over several years.